Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions

PURPOSE: Response to clopidogrel varies widely with nonresponse rates ranging from 4% to 30%. A reduced function of the gene variant of the CYP2C19 has been associated with lower drug metabolite levels, and hence diminished platelet inhibition. Drugs that alter CYP2C19 activity may also mimic geneti...

Descripción completa

Detalles Bibliográficos
Autores principales: Saab, Yolande B, Zeenny, Rony, Ramadan, Wijdan H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590670/
https://www.ncbi.nlm.nih.gov/pubmed/26445541
http://dx.doi.org/10.2147/TCRM.S83293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590670/
https://www.ncbi.nlm.nih.gov/pubmed/26445541
http://dx.doi.org/10.2147/TCRM.S83293

Ejemplares similares